| CAR20.19.22 T-cells in Relapsed, Refractory B-cell Malignancies (NCT05094206) | Medical College of Wisconsin | 2022-06-30 |
| A Study to Evaluate the Safety and Anti-cancer Activity of Loncastuximab Tesirine in Combination With Other Anti-cancer Agents in Participants With Relapsed or Refractory B-cell Non-Hodgkin Lymphoma (LOTIS-7) (NCT04970901) | ADC Therapeutics S.A. | 2022-06-17 |
| MargheRITA (Remote Intelligence for Therapeutic Adherence) (NCT05260203) | Advice Pharma Group srl | 2022-06-04 |
| PRT1419 as Monotherapy or in Combination With Azacitidine or Venetoclax in R/R Myeloid or B-cell Malignancies (NCT05107856) | Prelude Therapeutics | 2022-03-22 |
| Safety, Tolerability, and Efficacy of AT101 in Patients With Relapsed or Refractory B-cell Non-Hodgkin's Lymphoma (NCT05338931) | AbClon | 2022-03-15 |
| A Study to Evaluate Adverse Events and Change in Disease Activity of Subcutaneous (SC) Epcoritamab As Monotherapy or Combined With Standard of Care Therapies in Adult Participants in China With B-Cell Non-Hodgkin Lymphoma (NCT05201248) | Genmab | 2022-03-10 |
| Anakinra for the Prevention of Cytokine Release Syndrome and Neurotoxicity in Patients With B-Cell Non-Hodgkin Lymphoma Receiving CD19-Targeted CAR-T Cell Therapy (NCT04359784) | Fred Hutchinson Cancer Center | 2021-12-27 |
| A Study of JMT601 in Participants With Relapsed or Refractory CD20-positive B-cell Non-Hodgkin Lymphoma (NCT06725524) | Shanghai JMT-Bio Inc. | 2021-10-12 |
| Study of PCLX-001 in R/R Advanced Solid Malignancies and B-cell Lymphoma (NCT04836195) | Pacylex Pharmaceuticals | 2021-09-14 |
| Clinical Study of HLA Haploidentical CAR-NK Cells Targeting CD19 in the Treatment of Refractory/Relapsed B-cell NHL (NCT04887012) | Second Affiliated Hospital, Zhejiang University, School of Medicine | 2021-05-01 |
| UCD19 CarT in Treatment of Pediatric B-ALL and B-NHL (NCT04544592) | University of Colorado, Denver | 2021-03-10 |
| A Study of AZD0486 in Subjects With B-Cell Non-Hodgkin Lymphoma (NCT04594642) | AstraZeneca | 2021-03-02 |
| Study of Zanubrutinib, Rituximab and Combination Chemotherapy in Newly-diagnosed Aggressive B-cell Non-Hodgkin Lymphoma (NCT05164770) | Shandong Provincial Hospital | 2021-03-01 |
| Immunogenicity and Safety of Commercially Available Vaccines Against SARS-CoV-2 (COVID-19) in Patients With Hematologic Malignancies (NCT04748185) | Mayo Clinic | 2021-01-28 |
| Acalabrutinib and Anti-CD19 CAR T-cell Therapy for the Treatment of B-cell Lymphoma (NCT04257578) | University of Washington | 2020-12-02 |
| A Study of GC022F CAR-T Cell Immunotherapy for Relapsed or Refractory B- NHL (NCT04412174) | Hebei Yanda Ludaopei Hospital | 2020-06-01 |
| Dose-escalation Study of Safety of PBCAR20A in Subjects With r/r NHL or r/r CLL/SLL (NCT04030195) | Precision BioSciences, Inc. | 2020-03-24 |
| A Study of Anakinra to Prevent or Treat Severe Side Effects for Patients Receiving CAR-T Cell Therapy (NCT04148430) | Memorial Sloan Kettering Cancer Center | 2019-10-30 |
| Autologous CD22 CAR T Cells in Adults w/ Recurrent or Refractory B Cell Malignancies (NCT04088890) | Matthew Frank | 2019-09-12 |
| Treatment of Hematological Malignancy With Novel CAR-T Cells. (NCT04191941) | Timmune Biotech Inc. | 2019-09-01 |
| Study of Cosibelimab in Subjects With Relapsed or Refractory Lymphoma (NCT03778073) | TG Therapeutics, Inc. | 2019-04-17 |
| A Phase Ib/II Study Investigating the Safety, Tolerability, Pharmacokinetics, and Efficacy of Mosunetuzumab (BTCT4465A) in Combination With CHOP or CHP-Polatuzumab Vedotin in Participants With B-Cell Non-Hodgkin Lymphoma (NCT03677141) | Hoffmann-La Roche | 2019-03-08 |
| Nivolumab and Combination Chemotherapy in Treating Participants With Diffuse Large B-Cell Lymphoma (NCT03704714) | Northwestern University | 2018-11-20 |
| A Study to Evaluate the Safety and Efficacy of Mosunetuzumab (BTCT4465A) in Combination With Polatuzumab Vedotin in B-Cell Non-Hodgkin Lymphoma (NCT03671018) | Hoffmann-La Roche | 2018-09-25 |
| Tailored Prednisone Reduction in Preventing Hyperglycemia in Participants With B-Cell Non-Hodgkin Lymphoma Receiving Combination Chemotherapy Treatment (NCT03505762) | Wake Forest University Health Sciences | 2018-07-19 |
| TLR9 Agonist SD-101, Anti-OX40 Antibody BMS 986178, and Radiation Therapy in Treating Patients With Low-Grade B-Cell Non-Hodgkin Lymphomas (NCT03410901) | Ronald Levy | 2018-04-09 |
| A PhaseⅠb Study Evaluating Safety and Efficacy of C-CAR011 Treatment in B- NHL Subjects (NCT03483688) | Peking Union Medical College Hospital | 2018-03-06 |
| Combination of Pembrolizumab With TGR-1202 in Patients With Relapsed/Refractory CLL and B-cell NHL (NCT03283137) | University of Chicago | 2018-01-23 |
| Fludarabine Phosphate, Cyclophosphamide, Total Body Irradiation, and Donor Stem Cell Transplant in Treating Patients With Blood Cancer (NCT03333486) | Roswell Park Cancer Institute | 2017-12-07 |
| Study to Assess Safety, Tolerability, Pharmacokinetics and Antitumor Activity of AZD4573 in Relapsed/Refractory Haematological Malignancies (NCT03263637) | AstraZeneca | 2017-10-24 |
| A Study of Blinatumomab in Patients With Pre B-cell ALL and B-cell NHL as Post-allo-HSCT Remission Maintenance (NCT03114865) | Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins | 2017-09-05 |
| Management of Platelet Transfusion Therapy in Patients With Blood Cancer or Treatment-Induced Thrombocytopenia (NCT03195010) | Fred Hutchinson Cancer Center | 2017-06-09 |
| A Vaccine (VSV-hIFNβ-NIS) With or Without Cyclophosphamide and Combinations of Ipilimumab, Nivolumab, and Cemiplimab in Treating Relapsed or Refractory Multiple Myeloma, Acute Myeloid Leukemia or Lymphoma (NCT03017820) | Mayo Clinic | 2017-04-04 |
| Pilot Study of Pembrolizumab Treatment for Disease Relapse After Allogeneic Stem Cell Transplantation (NCT02981914) | University of Chicago | 2017-03-07 |
| Identifying, Understanding, and Overcoming Barriers to the Use of Clinical Practice Guidelines in Pediatric Oncology (NCT02847130) | Children's Oncology Group | 2016-11-21 |
| Mechanisms of Idelalisib-Associated Diarrhea in Patients With Relapsed Chronic Lymphocytic Leukemia, Indolent Non-hodgkin Lymphoma, or Small Lymphocytic Lymphoma (NCT02928510) | Jonsson Comprehensive Cancer Center | 2016-02-01 |
| DNA Sequencing-Based Monitoring of Minimal Residual Disease to Predict Clinical Relapse in Aggressive B-cell Non-Hodgkin Lymphomas (NCT02633111) | Memorial Sloan Kettering Cancer Center | 2015-10-01 |
| CD8+ Memory T-Cells as Consolidative Therapy After Donor Non-myeloablative Hematopoietic Cell Transplant in Treating Patients With Leukemia or Lymphoma (NCT02424968) | Robert Lowsky | 2015-06-01 |
| Open-Label Extension Study of De-immunized DI-Leu16-IL2 Immunocytokine Administered in Participants With B-cell NHL (NCT02151903) | Alopexx Oncology, LLC | 2014-11-04 |
| A Study of De-immunized DI-Leu16-IL2 Administered Subcutaneously in Participants With B-cell NHL (NCT01874288) | Alopexx Oncology, LLC | 2013-11-25 |
| Lenalidomide and Ipilimumab After Stem Cell Transplant in Treating Patients With Hematologic or Lymphoid Malignancies (NCT01919619) | M.D. Anderson Cancer Center | 2013-11-04 |
| Intergroup Randomized Trial for Children or Adolescents With B-Cell Non Hodgkin Lymphoma or B-Acute Leukemia: Rituximab Evaluation in High Risk Patients (NCT01516580) | Gustave Roussy, Cancer Campus, Grand Paris | 2011-12-01 |
| Bortezomib and Vorinostat as Maintenance Therapy After Autologous Stem Cell Transplant in Treating Patients With Non-Hodgkin Lymphoma (NCT00992446) | Fred Hutchinson Cancer Center | 2010-09-02 |